Listing Conference of FGD for CHB Indications -“Fuganding® TDF” Held in Beijing
Approval of TDF bulk drug and capsules in May, 2017 helps Cosunter become the only enterprise to have the two priority anti-HBV medicines of TDF and ETV, with the most complete production line in the anti-HBV field in China.
Cosunter Obtains 1st Approval for Production of TDF for HBV Indications
On May 18, the important medicine of Fujian Cosunter Pharmaceutical Co., Ltd., “Fuganding-Tenofovir Disoproxil Fumarate Capsules (Approval No.:SFDA 2017H0005) is successfully approved.
Clinical Data Collected over Three Years from TDF-ETV Non-inferiority Control Trial by Cosunter First Released Globally at APASL Annual Meeting 2017
The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) was held at Shanghai International Convention Center on February 15 - 19, 2017 in Shanghai, China.
PRC Online Drug Information Service Certificate No.：(M)-Non-operating-2014-0006
Copyright @ Cosunter Co., Ltd. 2006-2016. All rights reserved
M. ICP. B. No. 11026770 Website statistics